Clinical Consultants to Provide Regulatory, Development Help to Futura Surgicare

Novo Integrated Sciences Inc. and Clinical Consultants International LLC (CCI), a Novo wholly-owned subsidiary, has signed a consulting services agreement with Futura Surgicare Pvt. Ltd., an India-based manufacturer of wound closure and surgical products that are marketed and distributed in more than 70 countries under the trade name Dolphin Sutures. 
 
The agreement calls for CCI to help Futura obtain U.S. Food and Drug Administration (FDA) 510(k) approvals for its advanced surgical products, and for the two companies to work together to introduce Dolphin Sutures and mesh products to the North American healthcare market, potentially bringing substantial cost savings and improved care to American patients and healthcare providers.
 
“We are proud to partner with Futura in bringing Dolphin Sutures and mesh products to the North American market,” CCI President Dr. Joseph M. Chalil, M.D., said. “FDA approval of these products would symbolize a beacon of hope in addressing the high costs of the American healthcare market. We are confident this partnership will mark a significant milestone in offering affordable and superior surgical solutions.”
 
Futura Surgicare Pvt. Ltd. develops surgical sutures, including Polyglycolic Acid, Polyglactin 910, PTFE, and Barbed sutures. Leveraging 30 years of industry leadership from Bangalore, India, the company is recognized for its firsts in synthetic absorbable sutures and its globally sourced materials. Futura is accredited with ISO 9001:2008, ISO 13485, CE2460, WHO-GMP, and GLP certifications. The company’s product offering encompasses surgical sutures, skin staplers, hernia meshes, surgical tapes, hemostats, and bone wax.
 
Established in 2006 in Michigan as a hospital consulting firm, today CCI is a global consulting firm specializing in providing value-added services for the pharmaceutical, biotech, healthcare management, hospital management, medical marketing and strategic planning, health policy, and medical device sectors. Headquartered in Boca Raton, Fla., the company leverages more than 30 years of industry experience and expert consultants worldwide to support clients.
 
Novo Integrated Sciences Inc. takes a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem of services and product innovation. Novo offers a differentiated solution to deliver services and products through the integration of medical technology, advanced therapeutics, and rehabilitative science. The company’s decentralized healthcare business model is centered on three primary pillars to best support the transformation of non-catastrophic healthcare delivery to patients and consumers: Service networks, technology, and products.